← Back to Clinical Trials
Recruiting NCT07629674

NCT07629674 Visual Stimulation Through Video Therapy to Enhance Lower Limb Motor Recovery After Stroke

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07629674
Status Recruiting
Phase
Sponsor Centre Hospitalier Universitaire de Saint Etienne
Condition Hemiparetic Stroke
Study Type INTERVENTIONAL
Enrollment 12 participants
Start Date 2026-07-09
Primary Completion 2027-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 80 Years
Study Type INTERVENTIONAL
Interventions
Active VideotherapySham videotherapy

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 12 participants in total. It began in 2026-07-09 with a primary completion date of 2027-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This pilot study evaluates video therapy for lower limb motor recovery after stroke, an approach remains insufficiently documented. This single-center pilot study uses a Single-Case Experimental Design (SCED) to evaluate the effects of intensive video therapy combined with conventional rehabilitation in patients with subacute or chronic post-stroke hemiparesis. Twelve participants will be included and allocated to different baseline durations according to a multiple-baseline SCED design. The primary outcome is functional mobility, assessed using the Timed Up and Go (TUG) test, measured repeatedly throughout baseline, intervention, and follow-up phases.

Eligibility Criteria

Inclusion Criteria: * \- First or recurrent hemispheric ischemic or hemorrhagic stroke in the subacute or chronic phase (from 1 month to 1 year post-stroke). * Currently receiving rehabilitation care in a Physical Medicine and Rehabilitation (PM\&R) department * Able to walk 3 meters back and forth, with or without an assistive device. * Provided informed consent, signed jointly with the investigator. Exclusion Criteria: * \- Severe hemispatial neglect. * Severe spasticity impairing proper positioning (Modified Ashworth Scale \> 3). * Severe general disabling medical conditions. * Associated cerebellar syndrome. * Major comprehension disorders, psychiatric illness, or cognitive impairments that could interfere with study participation. * Participants under full legal guardianship (tutorship). * Pregnant or breastfeeding women.

Contact & Investigator

Central Contact

Etienne OJARDIAS, Dr

✉ Etienne.Ojardias@chu-st-etienne.fr

📞 0477127018

Principal Investigator

Etienne OJARDIAS, Dr

PRINCIPAL INVESTIGATOR

Centre Hospitalier Universitaire de Saint Etienne

Frequently Asked Questions

Who can join the NCT07629674 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Hemiparetic Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07629674 currently recruiting?

Yes, NCT07629674 is actively recruiting participants. Contact the research team at Etienne.Ojardias@chu-st-etienne.fr for enrollment information.

Where is the NCT07629674 trial being conducted?

This trial is being conducted at Saint-Etienne, France.

Who is sponsoring the NCT07629674 clinical trial?

NCT07629674 is sponsored by Centre Hospitalier Universitaire de Saint Etienne. The principal investigator is Etienne OJARDIAS, Dr at Centre Hospitalier Universitaire de Saint Etienne. The trial plans to enroll 12 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology